MediciNova seeks PhIII funding for acute asthma drug despite PhIIb disappointment
This article was originally published in Scrip
Executive Summary
After MediciNova president and CEO Yuichi Iwaki announced that MN-221 (bedoradrine), an intravenous drug to treat asthma exacerbations, failed to meet its primary endpoint in a Phase IIb study, he flew to Japan to convince the San Diego company's partner, Kissei Pharmaceutical, that the beta2-adrenergic receptor agonist is worth additional investment.